Citations

Clear

1727 citation(s) found for "So, Alan".

Injectable conductive hydrogel restores conduction through ablated myocardium
Zyl, Martin van , Pedrotty, Dawn , Kuzmenko, Volodymyr , Sämfors, Sanna, Livia, Christopher , Vaidya, Vaibhav R. , Sugrue, Alan , Behfar, Atta , Asirvatham, Samuel J. , Gatenholm, Paul , Kapa, Suraj , van Zyl, Martin , Livia, Christopher , Vaidya, Vaibhav , Sugrue, Alan , Asirvatham, Samuel J , Gatenholm, Paul , Kapa, Suraj , Behfar, Atta , Karabulut, Erdem , McLeod, Christopher J.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 23, 2020 | Volume: 31 | Issue: 12 | Pages: 3293-3301

10.1111/jce.14762 | PMID 32966655 Get It

AbstractIntroductionTherapies for substrate‐related arrhythmias include ablation or drugs targeted at altering conductive properties or disruption of slow zones in heterogeneous myocardium. Conductive compounds such as carbon nanotubes may provide a novel personalizable therapy for arrhythmia treatment by allowing tissue homogenization.MethodsA nanocellulose carbon nanotube‐conductive hydrogel was developed to have conduction properties similar to normal myocardium. Ex vivo perfused canine hearts were studied. Electroanatomic activation mapping of the epicardial surface was performed at baseline, after radiofrequency ablation, and after uniform needle injections of the conductive hydrogel through the injured tissue. Gross histology was used to assess distribution of conductive hydrogel in the tissue.ResultsThe conductive hydrogel viscosity was optimized to decrease with increasing shear rate to allow expression through a syringe. The direct current conductivity under aqueous conduction was 4.3 × 10−1 S/cm. In four canine hearts, when compared with the homogeneous baseline conduction, isochronal maps demonstrated sequential myocardial activation with a shift in direction of activation to surround the edges of the ablated region. After injection of the conductive hydrogel, isochrones demonstrated conduction through the ablated tissue with activation restored through the ablated tissue. Gross specimen examination demonstrated retention of the hydrogel within the tissue.ConclusionsThis proof‐of‐concept study demonstrates that conductive hydrogel can be injected into acutely disrupted myocardium to restore conduction. Future experiments should focus on evaluating long‐term retention and biocompatibility of the hydrogel through in vivo experimentation.
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)
Innocenti, Federico , Sibley, Alexander B. , Patil, Sushant, Etheridge, Amy S. , Jiang, Chen , Ou, Fang‐Shu , Howell, Stefanie , Plummer, Sarah J. , Bertagnolli, Monica M. , McLeod, Howard L. , Auman, J. Todd , Blanke, Charles D. , Furukawa, Yoichi , Kubo, Michiaki , Lenz, Heinz‐Josef , Ratain, Mark J. , Owzar, Kouros , Bertagnolli, Monica M , McLeod, Howard L , Auman, James T , Furukawa, Yoichi , Venook, Alan P , Kubo, Michiaki , Lenz, Heinz-Josef , Parker, Joel S , Ou, Fang-Shu , Casey, Graham , Venook, Alan P. , Parker, Joel S.

Mayo Clinic

Clinical Cancer Research | September 21, 2020 | Volume: 27 | Issue: 1 | Pages: 267-275

10.1158/1078-0432.ccr-20-2021 | PMID 32958699 Get It

Abstract Purpose: Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC). We aimed at identifying germline variants associated with survival in patients with mCRC treated with these regimens in Cancer and Leukemia Group B/SWOG 80405. Experimental Design: Patients with mCRC receiving either FOLFOX or FOLFIRI were randomized to either cetuximab or bevacizumab. DNA from peripheral blood was genotyped for approximately 700,000 SNPs. The association between SNPs and overall survival (OS) was tested in 613 patients of genetically estimated European ancestry using Cox proportional hazards models. Results: The four most significant SNPs associated with OS were three haplotypic SNPs between microsomal glutathione S-transferase 1 (MGST1) and LIM domain only 3 (LMO3, representative HR, 1.56; P = 1.30 × 10−6), and rs11644916 in AXIN1 (HR, 1.39, P = 4.26 × 10−6). AXIN1 is a well-established tumor suppressor gene in colorectal cancer, and rs11644916 (G>A) conferred shorter OS. Median OS for patients with the AA, AG, or GG genotypes was 18.4, 25.6, or 36.4 months, respectively. In 90 patients with stage IV colorectal cancer from The Cancer Genome Atlas (TCGA), rs11649255 in AXIN1 [in almost complete linkage disequilibrium (LD) with rs11644916], was associated with shorter OS (HR, 2.24, P = 0.0096). Using rs11648673 in AXIN1 (in very high LD with rs11644916 and with functional evidence), luciferase activity in three colorectal cancer cell lines was reduced. Conclusions: This is the first large genome-wide association study ever conducted in patients with mCRC treated with first-line standard treatment in a randomized phase III trial. A common SNP in AXIN1 conferred worse OS and the effect was replicated in TCGA. Further studies in colorectal cancer experimental models are required.
Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline
Newman, Connie B. , Boord, Jeffrey B. , Cariou, Bertrand , Chait, Alan , Fein, Henry G., Goldberg, Ira J. , Subramanian, Savitha , Tannock, Lisa R. , Blaha, Michael Joseph , Ginsberg, Henry N. , Murad, M. Hassan

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 20, 2020 | Volume: 105 | Issue: 12 | Pages: 3613-3682

10.1210/clinem/dgaa674 | PMID 32951056 Get It

Abstract Objective This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. Conclusion This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.
Personal Protective Equipment for Endoscopy in Low-Resource Settings During the COVID-19 Pandemic
Leddin, Desmond , Armstrong, David , Barkun, Alan , Butt, Amna Subhan , Khara, Harshit S. , Lee, Yeong Yeh , Makhoul, Elias, Saurin, Jean‐Christophe , Topazian, Mark , Thomson, S R , Veitch, Andrew , Wu, Kaichun , Lee, Yeong Yeh , Barkun, Alan N , Ali, Raja Affendi Raja , Chen, Ye , Leung, Wai K. , Macrae, Finlay , Makharia, Govind , Malekzadeh, Reza , Sadeghı, Anahita , Armstrong, David

Mayo Clinic

Journal of Clinical Gastroenterology | September 9, 2020 | Volume: 54 | Issue: 10 | Pages: 833-840

10.1097/mcg.0000000000001411 | PMID 32909973 Get It

Performance of endoscopic procedures is associated with a risk of infection from COVID-19. This risk can be reduced by the use of personal protective equipment (PPE). However, shortage of PPE has emerged as an important issue in managing the pandemic in both traditionally high and low-resource areas. A group of clinicians and researchers from thirteen countries representing low, middle, and high-income areas has developed recommendations for optimal utilization of PPE before, during, and after gastrointestinal endoscopy with particular reference to low-resource situations. We determined that there is limited flexibility with regard to the utilization of PPE between ideal and low-resource settings. Some compromises are possible, especially with regard to PPE use, during endoscopic procedures. We have, therefore, also stressed the need to prevent transmission of COVID-19 by measures other than PPE and to conserve PPE by reduction of patient volume, limiting procedures to urgent or emergent, and reducing the number of staff and trainees involved in procedures. This guidance aims to optimize utilization of PPE and protection of health care providers.
C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity
Baskaran, Pranetha , Gomez-Deza, Jorge, Chen, Han-Jou, Nishimura, Agnes L. , Adachi, Yoshitsugu, Stepto, Alan, Petrucelli, Leonard , Rogelj, Boris , Guthrie, Sarah , Shaw, Christopher E. , Chen, Han-Jou , Lee, Youn‐Bok , Smith, Bradley , Troakes, Claire , Gallo, Jean‐Marc , Hirth, Frank

Mayo Clinic

Human Molecular Genetics | September 4, 2020 | Volume: 30 | Issue: 3-4 | Pages: 318-320

10.1093/hmg/ddaa181 | PMID 32888026 Get It

Abstract LB-063: ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC
Johnson, Radia Marie , Qu, Xueping , Thomas, Joshua D. , Kschonsak, Yvonne T. , Huw, Ling‐Yuh, Sokol, Ethan S. , Ihuegbu, Nnamdi, Zill, Oliver A. , Kabbarah, Omar , Daemen, Anneleen , Venook, A., Innocenti, Federico , Lenz, Heinz‐Josef , Melo, Felipe de Sousa e , Bais, Carlos , Ou, Fang‐Shu , Bourgon, Richard , Venook, Alan P.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: LB-063-LB-063

10.1158/1538-7445.am2020-lb-063 Get It

Abstract Extensive biological and clinical evidence supports the notion many CRC tumors are addicted to EGFR/KRAS/MAPK signaling. For example, mutations in KRAS, BRAF and other MAPK pathway components confer intrinsic or acquired resistance to anti-EGFR therapy. However, a significant proportion of acquired resistance cases have remained unexplained. ARID1A mutations are found in approximately 11% of CRC tumors, but a connection between ARID1A mutations and EGFR/MAPK signaling activation in CRC has not been previously suspected. By leveraging the genomic biomarker data collected from 333 patients at baseline and at progression who participated in the CALGB/SWOG 80405 trial, we found that mutations in ARID1A, a key component of SWI/SNF complex, were enriched in the cell free DNA of 6/16 of the patients whose tumors had become resistant to anti-EGFR therapy with ARID1A mutations detected at either timepoint (adj. p = 0.03, OR = 0.09, two-tailed fisher's exact test). In contrast, there was no evidence of enriched ARID1A mutations in patients treated with bevacizumab. To investigate the potential role of a broader ARID1A deficiency phenotype in resistance to cetuximab therapy, we developed an ARID1A mutant-like signature from TCGA that captures the transcriptional profile characteristic of ARID1A mutants. Using this signature to stratify CALGB patients based on gene expression data collected on tissue at diagnosis, we also found patients with an ARID1A mutant-like gene expression profile had worst outcome in patients treated with cetuximab than bevacizumab with adjustment for established clinical variables for both OS [p = 0.0002, hazard ratio (HR) 6.2, 95% confidence interval (CI) 2.4-16], and PFS [p = 0.0008, HR 4.7 (1.9 -12)], suggesting that ARID1A mutations may be also a mechanism of intrinsic resistance to anti-EGFR therapies. Gene expression analysis demonstrated that ARID1A deficiency leads to re-activation of an EGFR-like signature, suggesting reactivation of this pathway as a possible mechanism of resistance. Furthermore, CRISPR knockout of ARID1A in the cetuximab-sensitive CRC cell line NCI-H508 conferred elevated MAPK signaling relative to parental line and resistance to cetuximab in culture. Consistent with these findings, we also observed strong mutual exclusivity between ARID1A mutations and mutations in the EGFR/MAPK signaling pathway in more than 40,000 lung and colorectal cancer patients profiled in the FoundationCore® database. Strikingly, in lung cancers where EGFR mutations structural variants (SV) are more prevalent, EGFR SV was the top mutually exclusive alteration with ARID1A mutations in lung cancers. Of 5980 lung cancer patients with ARID1A and/or EGFR SVs, only 100 patients (1.7%) had both SVs. Taken together, our data suggest that ARID1A loss-of-function mutations may promote resistance to cetuximab by driving an EGFR-like transcription program in the absence of ligand-dependent activation of EGFR. Our results suggest that ARID1A defects could be potentially used as an exclusion biomarker for cetuximab treatment decisions, and they provide a rationale for exploring therapeutic MAPK inhibition in ARID1A mutant CRC patients. Citation Format: Radia Marie Johnson, Xueping Qu, Joshua Thomas, Yvonne Kschonsak, Ling-Yuh Huw, Fang-Shu Ou, Ethan Sokol, Nnamdi Ihuegbu, Oliver Zill, Omar Kabbarah, Anneleen Daemen, Richard Bourgon, Alan Venook, Federico Innocenti, Heinz-Josef Lenz, Felipe de Sousa e Melo, Carlos Bais. ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr LB-063.
Abstract 1200: Associations between genetically predicted blood protein biomarkers and pancreatic ductal adenocarcinoma risk
Zhu, Jingjing , Shu, Xiao-Ou , Liu, Duo , Du, Mengmeng , Goodman, Phyllis J. , Li, Donghui , Bracci, Paige M. , Gallinger, Steven, Eeden, Stephen Van Den, Wolpin, Brian M. , Scélo, Ghislaine , Visvanatha, Kala, Haiman, Christopher A. , Petersen, Gloria M. , Zheng, Wei , Wu, Lang , Zheng, Wei , Guo, Xingyi , Bao, Jiandong , Milne, Roger L. , Giles, Graham G. , Wu, Chong , White, Emily , Risch, Harvey A. , Malats, Núria , Duell, Eric J. , Katzke, Verena , Neale, Rachel Ε. , Arslan, Alan A. , Canzian, Federico , Kooperberg, Charles , Freeman, Laura E. Beane , Marchand, Loı̈c Le , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Ámundadóttir, Laufey T. , Cai, Qiuyin , Long, Jirong , Shu, Xiao‐Ou

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 1200-1200

10.1158/1538-7445.am2020-1200 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of most lethal malignancies with few known risk factors and biomarkers. Identification of disease biomarkers is critical for understanding the pathogenesis of this cancer and identifying high risk individuals for close surveillance. Several blood protein biomarkers have been linked to PDAC in previous studies, but these studies have assessed only a limited number of biomarkers usually in small samples. To identify novel circulating protein biomarkers of PDAC, we studied 8,280 cases and 6,728 controls of European descent from the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case-Control Consortium, by using genetic instruments. Protein quantitative trait loci (pQTLs) for 1,226 plasma proteins identified in a large INTERVAL study of 3,301 healthy European descendants were used as instruments to evaluate associations between genetically predicted protein levels and PDAC. For proteins showing a significant association, we further conducted conditional analysis with adjustments for previously identified risk variants to assess whether the observed associations between genetically predicted protein concentrations and PDAC risk were independent of the risk variants identified in genome-wide association studies (GWAS). Furthermore, for the proteins that were associated with PDAC risk, we performed an enrichment analysis of the genes encoding these proteins to examine whether they are enriched in specific pathways, functions or networks. We observed associations between predicted concentrations of 38 proteins and PDAC risk at a false discovery rate of < 0.05, including those of 23 proteins that showed a significant association even after Bonferroni correction (4.08 × 10−5). These include Histo-blood group ABO system transferase encoded by ABO, which has been previously implicated as a potential target gene of PDAC risk variant identified in GWAS. Eight of the identified proteins (Beta-crystallin B2, Dedicator of cytokinesis protein 9, VIP36-like protein, Erythrocyte band 7 integral membrane protein, Tensin-2, Transmembrane protease serine 11D, Alcohol dehydrogenase 1B, and C-X-C motif chemokine 10) were associated with PDAC risk after conditioning on previously reported pancreatic cancer risk variants (odds ratios ranged from 0.79 to 1.52, P-values from 1.28 × 10−3 to 6.47 × 10−4). Pathway enrichment analysis showed that the encoding genes for the implicated proteins were significantly enriched in cancer-related pathways, such as STAT3 and IL-15 production. In conclusion, we identified 38 protein biomarker candidates for PDAC risk, which if validated by additional studies, may contribute to the etiological understanding of PDAC tumor development. Citation Format: Jingjing Zhu, Xiang Shu, Xingyi Guo, Duo Liu, Jiandong bao, Roger Milne, Graham G Giles, Chong Wu, Mengmeng Du, Emily White, Harvey A Risch, Nuria Malats, Eric J. Duell, Phyllis J. Goodman, Donghui Li, Paige Bracci, Verena Katzke, Rachel E Neale, Steven Gallinger, Stephen Van Den Eeden, Alan Arslan, Federico Canzian, Charles Kooperberg, Brian Wolpin, Laura Beane-Freeman, Ghislaine Scelo, Kala Visvanatha, Christopher A. Haiman, Loïc Le Marchand, Herbert Yu, Gloria M Petersen, Rachael Stolzenberg-Solomon, Alison P Klein, Laufey T Amundadottir, Qiuyin Cai, Jirong Long, Xiao-Ou Shu, Wei Zheng, Lang Wu. Associations between genetically predicted blood protein biomarkers and pancreatic ductal adenocarcinoma risk [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1200.
The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study—N05C31
Kottschade, Lisa A. , Sloan, Jeff A. , Mazurczak, Miroslaw, Johnson, David B. , Murphy, Brittany L. , Rowland, Kendrith M. , Berg, Alan R., Stella, Philip J., Loprinzi, Charles L. , Murphy, B., Smith, Daniel Arnold

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 9532-9532

10.1200/jco.2009.27.15_suppl.9532 Get It

9532 Background: Chemotherapy induced peripheral neuropathy (CIPN) continues to be a substantial problem for many cancer patients (pts). Pursuant to promising appearing pilot data, the current study evaluated the use of vitamin E for the prevention of CIPN. Methods: A phase III, randomized, double-blind, placebo controlled study was conducted in pts undergoing therapy with neurotoxic chemotherapy, utilizing twice daily dosing of vitamin E (400mg)/placebo. The primary endpoint was the incidence of grade 2+ sensory neuropathy (SN) toxicity (CTCAE v 3.0) in each treatment arm, analyzed by Chi-square testing. Major eligibility criteria included: planned curative intent adjuvant chemotherapy with neurotoxic chemotherapy, ≥ 18 years of age, ECOG PS of ≤2, no existing peripheral neuropathy or coronary artery disease, no prior treatment with neurotoxic chemotherapy, and no concurrent treatment with neuropathic or opioid pain medication. Planned sample size was 100 patients per arm, to provide 80% power to detect a difference in incidence of grade 2+ SN toxicity from 25% in the placebo group to 10% in the vitamin E group. Results: Two-hundred seven pts were enrolled between 12/01/2006 and 12/14/2007. Cytotoxic agents included taxanes (109), cisplatin (8), carboplatin (2), oxaliplatin (50) or combination (20). Eleven pts canceled prior to starting treatment and there were 7 ineligible pts on study. Thus there were 189 evaluable pts included in the current analysis. In this analysis, there was no difference in the incidence of grade 2+ SN between the 2 arms (vitamin E- 34% [95% CI- 25.0–44.8%] placebo- 29% [20.1–39.4%]; P=0.43). There, likewise, were no significant differences between treatment arms for time to onset of neuropathy (P= 0.72), for chemotherapy dose reductions due to neuropathy (P= 0.21) or patient questionnaire reported neuropathy symptoms. The treatment was well tolerated overall. Conclusions: Vitamin E did not appear to reduce the incidence of sensory neuropathy in the studied group of patients receiving neurotoxic chemotherapy but it appeared to be well tolerated. No significant financial relationships to disclose.
Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Bertolacci, Gregory J, Cunningham, Matthew , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Abegaz, Kedir Hussein , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Advani, Shailesh M, Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alanezi, Fahad , Alema, Niguse Meles , Wassihun, Biresaw , Ali, Beriwan Abdulqadir, Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Anvari, Davood , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barzegar, Akbar , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhagavathula, Akshaya Srikanth , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bhutta, Zulfiqar A , Bibi, Sadia , Bijani, Ali , Borschmann, Rohan , Borzì, Antonio Maria , Braithwaite, Dejana , Брико, Н. И. , Brugha, Traolach , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chapman, Jens R. , Chattu, Vijay Kumar , Chattu, Soosanna Kumary , Chaudhary, Neha , Cho, Daniel , Choi, Jee-Young J, Chowdhury, Mohiuddin Ahsanul Kabir , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Dávila-Cervantes, Claudio Alberto , Leo, Diego De, Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Elemineh, Demelash Abewa , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Eyawo, Oghenowede , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fereshtehnejad, Seyed-Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Fomenkov, Artem Alekseevich , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebremariam, Hadush, Gebremedhin, Ketema Bizuwork , Gebremeskel, Leake , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Gheshlagh, Reza Ghanei , Gholamian, Asadollah , Gilani, Syed Amir , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haagsma, Juanita A. , Hall, Brian J. , Hamadeh, Randah R , Hassan, Shoaib, Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Inbaraj, Leeberk Raja , Irvani, Seyed Sina Naghibi , Islam, M. Mofizul , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jahani, Mohammad Ali, Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kayode, Gbenga A , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Maseer , Khan, Ejaz Ahmad , Khan, Junaid , Khanna, Tripti, Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Sezer , Kısa, Adnan , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Koolivand, Ali , Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Manasi , Kumar, Vivek , Kumar, Narinder , Kumaresh, Girikumar, Lami, Faris , Lasrado, Savita , Leasher, Janet L , Li, Shanshan , Liu, Xuefeng , Lyons, Ronan A , Machado, Daiane Borges , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Mehndiratta, Man Mohan, Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Mohammed, Jemal , Bandpei, Mohammad Ali Mohseni, Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moradi, Masoud , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Musa, Kamarul Imran , Mustafa, Ghulam , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nguyen, Diep Ngoc , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Полибин, Р. В. , Polinder, Suzanne, Pourmalek, Farshad , Pourshams, Akram , Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Rao, Sowmya J, Rashedi, Vahid , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Saddik, Basema , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salem, Marwa Rashad , Salem, Hosni , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Soriano, Joan B. , Soyiri, Ireneous N , Sufiyan, Mu’awiyyah Babale , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tefera, Yibekal Manaye , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Титова, М. В. , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Tsatsakis, Aristidis , Car, Lorainne Tudor , Ullah, Irfan , Ullah, Saif , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Wu, Ai-Min, Wyper, Grant M. A. , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Ye, Pengpeng , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zarei, Fatemeh , Zhang, Zhi-Jiang, Zhang, Yunquan , Zodpey, Sanjay , Dandona, Rakhi , Dharmaratne, Samath Dhamminda , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Vos, Theo , Topór‐Mądry, Roman , Feyissa, Garumma Tolu , Haghparast‐Bidgoli, Hassan , Kumar, G Anil , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Bhagavathula, Akshaya Srikanth , Belete, T , Liu, Zichen , Roberts, Nicholas L S , Henry, Nathaniel J , Abdollahpour, Ibrahim , Adsuar, José Carmelo , Ahmed, Muktar Beshir , Ahmed, Rushdiá , Alghnam, Suliman Abdullah , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Banach, Maciej , Bayati, Mohsen , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Benseñor, Isabela M. , Boloor, Archith , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Cicuttini, Flavia , Coelho, João M, Dahlawi, Saad M A , Daryani, Ahmad , Demeke, Feleke Mekonnen , Forooshani, Zahra Sadat Dibaji, Do, Hoa , Duko, Bereket , El-Jaafary, Shaimaa I , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Foroutan, Masoud , Franklin, Richard C. , Gebremariam, Hadush, Gedefaw, Getnet , Bante, Agegnehu , Gill, Tiffany K. , Goudarzian, Amir Hossein , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Hamidi, Samer , Handiso, Demelash Woldeyohannes , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jones, Kelly , Jozwiak, Jacek Jerzy , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Khalil, Ibrahim A, Khazaei, Salman , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Lansingh, Van Charles , Latifi, Arman , Lauriola, Paolo , Vecchia, Carlo La , Lee, Shaun Wen Huey , Lopez, Alan D , Lotufo, Paulo A. , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Aschalew, Zeleke , Meštrović, Tomislav , Mirică, Andreea , Mirzaei-Alavijeh, Mehdi, Moazen, Babak , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Mohebi, Farnam , Moradi‐Lakeh, Maziar , Moradzadeh, Rahmatollah , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nazari, Javad , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rahimi, Siavash , Rastogi, Prateek , Rathi, Priya , Rawaf, Salman , Ribeiro, Ana Isabel , Ríos-González, Carlos Miguel , Roever, Leonardo , Ronfani, Luca , Roshandel, Gholamreza , Safarpour, Hamid , Salamati, Payman, Santric-Milicevic, Milena M , Sarker, Abdur Razzaque , Sayyah, Mehdi , Shahabi, Saeed , Sheikh, Aziz , Siabani, Soraya , Singh, Ambrish , Soheili, Amin , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Khanh Bao , Tran, Bach Xuan , Unnikrishnan, Bhaskaran , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Veisani, Yousef , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zhang, Zhi‐Jiang , Ziapour, Arash , Pigott, David M. , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | August 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i125-i153

10.1136/injuryprev-2019-043531 | PMID 32839249 Get It

Background While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria. Methods In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then estimating incidence for every cause of injury. Non-fatal disability for each cause is then calculated based on the probabilities of suffering from different types of bodily injury experienced. Results GBD 2017 produced morbidity and mortality estimates for 38 causes of injury. Estimates were produced in terms of incidence, prevalence, years lived with disability, cause-specific mortality, years of life lost and disability-adjusted life-years for a 28-year period for 22 age groups, 195 countries and both sexes. Conclusions GBD 2017 demonstrated a complex and sophisticated series of analytical steps using the largest known database of morbidity and mortality data on injuries. GBD 2017 results should be used to help inform injury prevention policy making and resource allocation. We also identify important avenues for improving injury burden estimation in the future.